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142Operative and nonoperative management
of chronic disseminated intravascular coagulation
due to persistent aortic endoleak
Jeffrey J. Nienaber, MD,a Audra A. Duncan, MD,a Gustavo S. Oderich, MD,a Rajiv K. Pruthi, MBBS,b
and William L. Nichols, MD,b Rochester, Minn
Disseminated intravascular coagulation (DIC) due to endoleak is a rare complication following endovascular aneurysm
repair. Two of the four previously reported cases occurred in patients with cirrhosis. We describe three patients with
normal liver function who developed DIC due to delayed high-ﬂow (type Ia or III) endoleaks. Two patients underwent
successful surgical repair, and the third was managed medically. All three patients had chronic thrombocytopenia prior to
developing an endoleak as did the four reported cases in the literature. We propose that thrombocytopenia, like cirrhosis,
be considered a risk factor for DIC due to endoleaks in patients undergoing endovascular aneurysm repair. (J Vasc Surg
2014;59:1426-9.)Fig 1. a, Computed tomography angiography (CTA) demon-PATIENT 1
An 89-year-old male presented 3 years after endovas-
cular aneurysm repair (EVAR) with a Talent device
(Medtronic Inc, Santa Rosa, Calif) for a 5-cm abdominal
aortic aneurysm (AAA). He had long-standing thrombo-
cytopenia (platelets, 142  109/L 1 year ago [normal,
150-450  109/L]) and recently underwent pacemaker
exchange complicated by recurrent wound hematomas
from disseminated intravascular coagulation (DIC; Inter-
national Society on Thrombosis and Hemostasis [ISTH]
score, 4), with a decrease in platelets to 76  109/L.
Fibrinogen was 120 mg/dL (normal, 200-375 mg/dL),
D-dimer was 14,900 ng/mL (normal, <250 ng/mL),
and liver function tests (LFTs) were normal. Initiation
of subcutaneous enoxaparin 80 mg/day resulted in
resolution of the hematomas and normalization of ﬁbrin-
ogen levels. Computed tomography angiography (CTA)
demonstrated a new type Ia endoleak (Fig 1, a) with
aneurysm sac enlargement from 4.5 cm to 5.0 cm over
6 months. The aortic neck diameter was 36 mm (Fig 1,
b), which precluded endovascular repair. He declined
open surgical repair. Platelet (93-132  109/L) and
ﬁbrinogen (119-321 mg/dL) levels remained stable on
enoxapfarin 60 mg daily for the next 2 years, although
D-dimer levels remained >2000 ng/mL. His endoleakstrating a large type Ia endoleak. b, CTA demonstrating large
infrarenal neck (red arrow, lowest [left] renal artery; yellow line,
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6persisted, and the aneurysm sac enlarged to 6.1 cm. He
died at age 91 from pneumonia.
PATIENT 2
This 80-year-old male underwent thoracic endovascu-
lar aneurysm repair (TEVAR) 8 years previously for
a 6.2-cm proximal descending thoracic aortic aneurysm.
Fig 2. a, Three weeks following carotid-carotid-subclavian sequential bypass, a Viabahn chimney graft (W. L. Gore &
Associates Inc) was positioned in the innominate artery via right brachial access, and a Medtronic Talent device
(Medtronic Inc) was used to extend the prior thoracic endovascular aneurysm repair (TEVAR) to the proximal aortic
arch. The proximal left subclavian artery was subsequently occluded with an Amplatzer Vascular Plug (St. Jude Medical,
St. Paul, Minn). b, Subsequent computed tomography angiography (CTA) illustrates the completed hybrid
debranching repair. c, Initial treatment of the recurrent endoleak with coil embolization and Onyx (ev3 Inc). d,
Rerecurrence of the endoleak prompted a second treatment with coil embolization and Onyx, with subsequent
resolution of the endoleak and sac shrinkage.
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penic purpura with a pre-TEVAR platelet count of 140 
109/L and subsequent open type IV thoracoabdominal
aortic aneurysm repair with no bleeding complications.
He was referred to us with a new type Ia endoleak and
a 10-cm aneurysm sac. He had progressive thrombocyto-
penia (77  109/L), with ﬁbrinogen of 126 mg/dL and
D-dimer levels >20,000 ng/mL, indicating DIC (ISTH
score, 4). He was clinically asymptomatic. LFTs were
normal. Cardiac comorbidities precluded open repair.
Preoperative dalteparin (2000 units subcutaneously daily)
resulted in an increase in platelets to 92  109/L and
ﬁbrinogen to 209 mg/dL.
The endoleak was treated by staged cervical debranch-
ing and proximal extension of the endograft usinga 46-mm Medtronic Talent device with an innominate
artery chimney Gore Viabahn endograft (W. L. Gore &
Associates Inc, Flagstaff, Ariz) (Fig 2, a and b). He received
20 units of cryoprecipitate and 3 units of platelets, and was
discharged 3 days later on dalteparin. DIC improved at 3
weeks (platelets, 181  109/L; ﬁbrinogen, 383 mg/dL).
The endoleak recurred 3 months later, causing recurrence
of DIC (platelets, 64  109/L; ﬁbrinogen, 143 mg/dL)
with easy bruising. The patient underwent two sessions
of sac coil embolization and Onyx (ev3 Inc, Bonn,
Germany) injection with ﬁnal resolution of the endoleak
(Fig 2, c and d). CTA 6 months later demonstrated no
endoleak and aneurysm shrinkage. Thrombocytopenia per-
sisted (platelets 60  109/L), however, but he declined
further workup and died 7 months later of cardiac disease.
Fig 3. Platelet count, ﬁbrinogen, and D-dimer levels in response
to surgery (OR) and transfusion of cryoglobulin (C, 20 units) or
platelets (P, 2 units, pooled).
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A 74-year-old male underwent EVAR with an
AneuRx device (Medtronic Inc) and aortic cuff 7 years
previously for a 5-cm AAA. His history included congen-
ital thrombocytopenia (pre-EVAR platelet count of
127  109/L) and a type II endoleak repair with
Onyx 5 years previously. More recently, he developed
clinical (bruising, epistaxis, hematuria) and laboratory
(thrombocytopenia, 81  109/L; hypoﬁbrinogenemia,
74 mg/dL; D-dimer, >20,000 ng/mL) evidence of
DIC (ISTH score, 5). LFTs were normal. CTA showed
a large proximal type I vs III endoleak with a reverse-
taper neck and enlargement of the sac from 4.9 to 5.5
cm over 8 months. He underwent open AAA repair
(inter-renal clamp, explantation, and reconstruction with
a tube graft). The endoleak was likely type III based
on intraoperative ﬁndings. He received 60 units of cryo-
precipitate, 6 units of packed red blood cells, 6 units of
fresh frozen plasma, and 5 units of platelets, and his esti-
mated blood loss was 1300 mL. He received 10 units of
cryoprecipitate the morning of surgery, and platelets
were not given until the aorta was cross-clamped. He
did not require any further products beyond 12 hours
postoperatively. On postoperative day 9, his platelets
(223  109/L) and ﬁbrinogen (428 mg/dL) were
normal, and the D-dimer had decreased to 4775 ng/
mL (Fig 3).
Three weeks postoperatively, he developed nausea,
low-grade fevers, and lost 20 pounds. His white blood
cell count was normal (platelets, 278  109/L; ﬁbrinogen,
742 mg/dL; and D-dimer, 2095 ng/mL). Laboratory
studies were remarkable for elevated C-reactive protein
(212 mg/L), alkaline phosphatase (253 U/L), aspartate
aminotransferase (378 U/L), and alanine aminotransferase
(336 U/L), with a total bilirubin of 1.2 mg/dL. Despite
extensive testing (two CT scans, two tagged white blood
cell scans, ultrasound, upper gastrointestinal endoscopy,
sinus CT, hepatobiliary iminodiacetic acid scan, and hepa-
titis serologies), no etiology was documented. He was
diagnosed with failure to thrive of unclear etiology. As
LFTs were normalizing and the patient was improving,
he was discharged. He died 2 months postoperatively of
unknown causes.
DISCUSSION
Of the four published cases of endoleak-induced DIC,
two had normal1,2 and two had abnormal liver function.3,4
The patient reported by Patel et al1 had preoperative
thrombocytopenia (108  109/L) and normal liver func-
tion. Repair of his type Ia endoleak by aortic banding
cured the DIC, and endovascular repair of a type 1b endo-
leak reported by Keo et al2 cured that patient’s DIC (base-
line platelets were 91  109/L from myelodysplasia). Our
report adds to the experience of those with normal liver
function. All of our patients developed DIC as a result of
large, delayed type Ia or III endoleaks with aneurysm sac
expansion, and all had mild thrombocytopenia and normalliver function with no pre-existing liver disease prior to
the initial aneurysm repair (two patients) and/or the
development of the endoleak (all three patients). None
of our patients had clinical evidence of thrombosis/
microthrombosis.
Higashiura et al3 described a known cirrhotic with
thrombocytopenia (46  109/L) who developed chronic
DIC due to type Ia/III endoleaks, and Pesteil et al4 pre-
sented a known cirrhotic with thrombocytopenia (110 
109/L) who developed DIC due to a type III endoleak
following TEVAR. Two other cases of severe DIC
following EVAR were described, although no endoleak
was identiﬁed as the etiology.5,6 We found no reports of
DIC due to type II or IV endoleaks. Whether thrombocy-
topenia was due to a separate disease that put these
patients at risk for DIC once an endoleak developed or
whether it was merely a marker of early/subclinical DIC
due to the original aneurysm itself is unclear, although
we would favor the latter.
Possible mechanisms of aneurysm and endoleak-
induced DIC have been reviewed previously.1-6 Generally,
it is hypothesized that turbulent ﬂow liberates coagulated
material from the aortic sac, exposing denuded endothe-
lium and tissue factor, leading to activation of coagulation
factors, excess generation of thrombin, chronic consump-
tion of clotting factors, and simultaneous excess plasmin
generation and ﬁbrinolysis of the clots. Heparin and deriv-
atives (eg, low-molecular-weight heparin) interrupt the
vicious cycle of thrombin generation and ameliorate the
DIC.7
For DIC in general, low-molecular-weight heparin is
preferable to unfractionated heparin and carries a level
B2 recommendation (B1 if thrombosis is present and D
with severe hemorrhage), although speciﬁc recommenda-
tions for endoleak-induced DIC are not available.7 Pro-
longed follow-up of platelet counts, ﬁbrinogen, and D-
dimer levels are necessary to ensure resolution of DIC, as
platelets and ﬁbrinogen can rise as acute-phase reactants
due to surgical intervention alone.
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